| |
| |
|
| Insider
Information: |
Graham G. Walmsley |
| Relationship: |
Director |
| City: |
South San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
8,168 |
|
|
Indirect Shares
|
8,340,856 |
|
|
| Direct
Value |
$1,440 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
8,349,024 |
|
|
| Total
Value |
$1,440 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
|
|
| Stock
price went down : |
|
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Akero Therapeutics, Inc. |
AKRO |
|
2023-12-08 |
2,168 |
2023-12-08 |
800,000 |
Premium* |
|
|
Alx Oncology Holdings Inc |
ALXO |
Director |
2020-07-21 |
0 |
2020-12-14 |
3,156,981 |
Premium* |
|
|
Science 37 Holdings, Inc |
SNCE |
Director |
2020-11-20 |
6,000 |
|
0 |
Premium* |
|
|
Olema Pharmaceuticals, Inc. |
OLMA |
Director |
2020-11-23 |
0 |
2023-12-05 |
4,383,875 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
18 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| AKRO |
Akero Therapeutics, Inc. |
|
– • – |
2023-12-08 |
4 |
B |
$19.80 |
$1,982,940 |
I/I |
100,000 |
800,000 |
0.01 |
- |
|
| OLMA |
Olema Pharmaceuticals, In... |
Director |
– • – |
2023-12-05 |
4 |
B |
$13.09 |
$1,871,280 |
I/I |
131,870 |
1,800,000 |
2.1 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
|
– • – |
2023-12-01 |
4 |
B |
$16.99 |
$849,730 |
I/I |
50,000 |
700,000 |
0.01 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
|
– • – |
2023-11-30 |
4 |
B |
$16.90 |
$844,835 |
I/I |
50,000 |
650,000 |
0.01 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
|
– • – |
2023-09-19 |
4 |
B |
$26.00 |
$10,400,000 |
I/I |
400,000 |
400,000 |
0.01 |
- |
|
| OLMA |
Olema Pharmaceuticals, In... |
Director |
– • – |
2023-09-12 |
4 |
B |
$9.84 |
$4,999,999 |
I/I |
508,130 |
1,668,130 |
2.1 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
|
– • – |
2023-08-08 |
4 |
B |
$42.06 |
$1,051,475 |
I/I |
25,000 |
600,000 |
0.01 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
|
– • – |
2023-08-01 |
4 |
B |
$43.26 |
$1,081,525 |
I/I |
25,000 |
575,000 |
0.01 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
|
– • – |
2023-07-28 |
4 |
B |
$42.69 |
$1,280,709 |
I/I |
30,000 |
550,000 |
0.01 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
|
– • – |
2023-05-19 |
4 |
B |
$42.00 |
$5,040,000 |
I/I |
120,000 |
520,000 |
0.01 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
Director |
– • – |
2022-09-19 |
4/A |
B |
$26.00 |
$10,400,000 |
I/I |
400,000 |
400,000 |
2.1 |
- |
|
| ALXO |
Alx Oncology Holdings Inc |
Director |
– • – |
2020-12-14 |
4 |
B |
$76.00 |
$1,520,000 |
I/I |
20,000 |
995,000 |
2.1 |
- |
|
| OLMA |
Olema Pharmaceuticals, In... |
Director |
– • – |
2020-11-23 |
4 |
B |
$19.00 |
$22,040,000 |
I/I |
1,160,000 |
1,160,000 |
2.1 |
- |
|
| OLMA |
Olema Pharmaceuticals, In... |
Director |
– • – |
2020-11-23 |
4 |
A |
$0.00 |
$0 |
I/I |
2,583,875 |
1,183,114 |
0 |
- |
|
| SNCE |
Science 37 Holdings, Inc |
Director |
– • – |
2020-11-20 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
6,000 |
|
- |
|
| ALXO |
Alx Oncology Holdings Inc |
Director |
– • – |
2020-07-21 |
4 |
B |
$19.00 |
$18,525,000 |
I/I |
975,000 |
975,000 |
2.1 |
- |
|
| ALXO |
Alx Oncology Holdings Inc |
Director |
– • – |
2020-07-21 |
4 |
A |
$0.00 |
$0 |
I/I |
2,105,901 |
2,161,981 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
Director |
– • – |
2020-03-30 |
4 |
OE |
$19.97 |
$43,295 |
D/D |
2,168 |
2,168 |
0 |
- |
|
18 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
